Management of CMV Infections after Bone Marrow Transplantation: A Paradigm Shift

References

• Wingard J R, Piantadosi S, Burns W H, et al. Cytomegalovirus infections in patients treated by intensive cytoreductive therapy with marrow transplant. Rev Infect Dis 1990; 12((Suppl. 7))S793–S804
   Google Scholar
• Winston D J, Ho W G, Howell C L, et al. Cytomegalovirus infections after allogeneic bone marrrow transplantation. Rev Infect Dis 1990; 12((Suppl 7))S776–S792
   Google Scholar
• Enright H, Haake R, Weisdorf D, et al. Cytomegalovirus pneumonia after bone marrow transplantation. Transplantation 1993; 55: 1339–1346
   PubMed Web of Science ®Google Scholar
• Meyers J D, Haake R, Thomas E D, et al. Risk factors for cytomegalovirus infection after human marrow transplantation. J Infect Dis 1986; 153: 478–488
   PubMed Web of Science ®Google Scholar
• Miller W, Flynn P, McCullough J, et al. Cytomegalovirus infection after marrow transplantation: an association with acute graft-versus-host disease. Blood 1986; 67: 1162–1167
   PubMed Web of Science ®Google Scholar
• Meyers J D, Ljungman P, Fisher L D. Cytomegalovirus excretion as a predictor of cytomegalovirus disease after marrow transplantation: importance of cytomegalovirus viremia. J Infect Dis 1990; 162: 373–380
   PubMed Web of Science ®Google Scholar
• Weiner R S, Bortin M M, Gale R P, et al. Interstitial pneumonitis after bone marrow transplantation. Ann Intern Med 1986; 104: 168–175
   PubMed Web of Science ®Google Scholar
• Wingard J R, Mellits E D, Sostrin M B, et al. Interstitial pneumonitis after allogeneic bone marrow transplantation: nine-year experience at a single institution. Medicine (Baltimore) 1988; 67: 175–186
   PubMed Web of Science ®Google Scholar
• Wingard J R, Chen D Y-H, Burns W H, et al. Cytomegalovirus infection after autologous bone marrow transplantation: comparison to infection after allogeneic bone marrow transplantation. Blood 1988; 71: 1432–1437
   PubMed Web of Science ®Google Scholar
• Appelbaum F R, Meyers J D, Fefer A, et al. Nonbacterial nonfungal pneumonia following marrow transplantation in 100 identical twins. Transplantation 1982; 33: 265–268
   PubMedGoogle Scholar
• Reusser P, Fisher L D, Buckner C D, et al. Cytomegalovirus infection after autologous bone marrow transplantation: occurrence of cytomegalovirus disease and effect on engraftment. Blood 1990; 75: 1888–1894
   PubMed Web of Science ®Google Scholar
• Ljungman P, Biron P, Bosi A, et al. Cytomegalovirus interstitial pneumonia in autologous bone marrow transplant recipients. Bone Marrow Transplant 1994; 13: 209–212
   Google Scholar
• Wingard J R, Sostrin M B, Vriesendorp H M, et al. Interstitial pneumonitis following autologous bone marrow transplantation. Transplantation 1988; 46: 61–65
   PubMed Web of Science ®Google Scholar
• Meyers J D, Flournoy N, Thomas E D. Nonbacterial pneumonia after allogeneic bone marrow transplantation: a review often years' experience. Rev Infect Dis 1982; 4: 1119–1132
   PubMedGoogle Scholar
• Paulin T, Ringden O, Lonnqvist B, et al. The importance of pre-bone marrow transplantation serology in determining subsequent cytomegalovirus infection: analysis of risk factors. Scand J Infect Dis 1986; 18: 199–209
   PubMed Web of Science ®Google Scholar
• Rasmussen L. Molecular pathogenesis of human cytomegalovirus infection. Transplant Infect Dis 1999; 1: 127–134
   PubMedGoogle Scholar
• Fries B C, Chou S, Boeckh M, et al. Frequency distribution of cytomegalovirus envelope glycoprotein genotypes in bone marrow transplant recipients. J Infect Dis 1994; 169: 769–774
   PubMed Web of Science ®Google Scholar
• Torok-Storb B, Boeckh M, Hoy C, et al. Association of specific cytomegalovirus genotypes with death from myelosuppression after marrow transplantation. Blood 1997; 90: 2097–2102
   Google Scholar
• DiPersio J, Martin B, Abboud C N, et al. Increased rates of CMV viremia in recipients of peripheral blood stem cell (PBSC) allogeneic transplants: rationale for both prophylactic therapy and short course single daily dosing of ganciclovir for 21 days. (Abstract 1685). Blood 1996; 88((Suppl 1))424a
   Google Scholar
• Atkinson K, Arthur C, Bradstock K, et al. Prophylactic ganciclovir is more effective in HLA-identical family member marrow transplant recipients than in more heavily immune-suppressed HLA-identical unrelated donor marrow transplant recipients. Bone Marrow Transplant 1995; 16: 401–405
   Google Scholar
• Takenaka K, Gondo H, Tanimoto K, et al. Increased incidence of cytomegalovirus (CMV) infection and CMV-associated disease after allogeneic bone marrow transplantation from unrelated donors. Bone Marrow Transplant 1997; 19: 241–248
   PubMedGoogle Scholar
• de la Camara R, Fernandez-Ranada J M. Increased incidence of CMV infection after allogeneic bone marrow transplantation from unrelated donors but doubts about an increase in CMV-associated disease. Bone Marrow Transplant 1997; 20: 181
   Google Scholar
• Enright H, Kaahe R, Weisdorf D, et al. Cytomegalovirus pneumonia after bone marrow transplantation. Transplantation 1993; 55: 1339–1346
   PubMed Web of Science ®Google Scholar
• Hertenstein B, Hampl W, Bunjes D, et al. In vivo/ex vivo T cell depletion for GVHD prophylaxis influences onset and course of active cytomegalovirus infection and disease after BMT. Bone Marrow Transplant 1995; 15: 387–393
   PubMed Web of Science ®Google Scholar
• Boeckh M, Bowden R A, Goodrish J M, et al. Cytomegalovirus antigen detection in peripheral blood leukocytes after allogeneic marrow transplantation. Blood 1992; 80: 1358–1364
   PubMed Web of Science ®Google Scholar
• Van der Bij W, Torensma R, van Son W J, et al. Rapid immunodiagnosis of active cytomegalovirus infection by monoclonal antibody staining of blood leucocytes. J Med Virol 1988; 25: 179–188
   PubMed Web of Science ®Google Scholar
• Jiwa N M, van de Rijke F M, Mulder A, et al. An improved immuno-cytochemical method for detection of human cytomegalovirus antigens in peripheral blood leucocytes. Histochemistry 1989; 95: 345–349
   Google Scholar
• Spector S A, Merrill R, Wolf D, et al. Detection of human cytomegalovirus in plasma of AIDS patients during acute visceral disease by DNA amplification. J Clin Microbiol 1992; 30: 2359–2365
   PubMed Web of Science ®Google Scholar
• Brytting M, Xu W, Wahren B, et al. Cytomegalovirus DNA detection in sera from patients with active cytomegalovirus infections. J Clin Microbiol 1992; 30: 1937–1941
   PubMed Web of Science ®Google Scholar
• Einsele H, Steidle M, Vallbracht A, et al. Early occurrence of human cytomegalovirus infection after bone marrow transplantation as demonstrated by the polymerase chain reaction technique. Blood 1991; 77: 1104–1110
   PubMedGoogle Scholar
• Nolte F S, Emmens R K, Thurmond C, et al. Early detection of human cytomegalovirus viremia in bone marrow transplant recipients by DNA amplification. J Clin Microbiol 1995; 33: 1263–1266
   Google Scholar
• Einsele H, Ehninger G, Hebart H, et al. Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation. Blood 1995; 86: 2815–2820
   PubMed Web of Science ®Google Scholar
• Boeckh M, Gallez-Hawkins G M, Myerson D, et al. Plasma polymerase chain reaction for cytomegalovirus DNA after allogeneic marrow transplantation. Transplantation 1997; 64: 108–113
   PubMed Web of Science ®Google Scholar
• Freymuth F, Gennetay E, Petitjean J, et al. Comparison of nested PCR for detection of DNA in plasma with pp65 leukocytic antigenemia procedure for diagnosis of human cytomegalovirus infection. J Clin Microbiol 1994; 32: 1614–1618
   PubMed Web of Science ®Google Scholar
• Crawford S W, Bowden R A, Hackman R C, et al. Rapid detection of cytomegalovirus pulmonary infection by bronchoalveolar lavage and centrifugation culture. Ann Intern Med 1988; 108: 180–185
   PubMed Web of Science ®Google Scholar
• Bratanow N C, Ash R C, Turner P A. Successful treatment of serious cytomegalovirus (CMV) disease with 9 (1,3-dihydroxy-2-propoxymethyl)guanine (ganciclovir), and intravenous immunoglobulin (IVIG) in bone marrow transplant (BMT) patients. (Abstract 254). Exp Hematol 1987; 15: 541
   Web of Science ®Google Scholar
• Emanuel D, Cunningham I, Jules-Elysee K, et al. Cytomegalovirus pneumonia after bone marrow transplantation successfully treated with the combination of ganciclovir and high-dose intravenous immune globulin. Ann Intern Med 1988; 109: 777–782
   PubMed Web of Science ®Google Scholar
• Reed E C, Bowden R A, Dandliker P S, et al. Treatment of cytomegalovirus pneumonia with ganciclovir and intravenous cytomegalovirus immunoglobulin in patients with bone marrow transplants. Ann Intern Med 1988; 109: 783–788
   PubMed Web of Science ®Google Scholar
• Schmidt G M, Kovacs A, Zaia J A, et al. Ganciclovir/immunoglobulin combination therapy for the treatment of human cytomegalovirus-associated interstitial pneumonia in bone marrow allograft recipients. Transplantation 1988; 46: 905–907
   PubMed Web of Science ®Google Scholar
• Aschan J, Ringden O, Ljungman P, et al. Foscarnet for treatment of cytomegalovirus infections in bone marrow transplant recipients. Scand J Infect Dis 1992; 24: 143–150
   PubMed Web of Science ®Google Scholar
• Reusser P, Gambertoglio J G, Lilleby K, et al. Phase I-II trial of foscarnet for prevention of cytomegalovirus infection in autologous and allogeneic marrow transplant recipients. J Infect Dis 1992; 166: 473–479
   PubMed Web of Science ®Google Scholar
• Bacigalupo A, Tedone E, Van Lint M T, et al. Treatment of ganciclovir resistant cytomegalovirus with foscarnet: a report of two cases occurring after bone marrow transplantation. Leuk Lymphoma 1994; 12: 477–481
   Google Scholar
• Bowden R A, Sayers M, Flournoy N, et al. Cytomegalovirus immune globulin and seronegative blood products to prevent primary cytomegalovirus infection after marrow transplantation. N Engj Med 1986; 314: 1006–1010
   PubMed Web of Science ®Google Scholar
• Mackinnon S, Burnett A K, Crawford R J, et al. Seronegative blood products prevent primary cytomegalovirus infection after bone marrow transplantation. J Clin Pathol 1988; 41: 948–950
   PubMed Web of Science ®Google Scholar
• Miller W, McCulough J, Balfour H H, et al. Prevention of CMV infection by blood products: a randomized trial. (Abstract K128) J Cell Biochem 1988; 12((Suppl C))93
   Google Scholar
• De Witte T, Schattenbereg A, Van Dijk B A, et al. Prevention of primary cytomegalovirus infection after allogeneic bone marrow transplantation by using leukocyte-poor random blood products from cytomegalovirus-unscreened blood-bank donors. Transplantation 1990; 50: 964–968
   Web of Science ®Google Scholar
• Bowden R A, Sayers M, Slichter S J, et al. Use of leukocyte-poor transfusions to prevent CMV infection after marrow transplantProc 2nd Int CMV Workshop, San Diego, CA, 1989
   Google Scholar
• Winston D J, Ho W G, Lin C H, et al. Intravenous immune globulin for prevention of cytomegalovirus infection and interstitial pneumonia after bone marrow transplantation. Ann Intern Med 1987; 106: 12–18
   PubMed Web of Science ®Google Scholar
• Bass E B, Powe N R, Goodman S N, et al. Efficacy of intravenous immune globulin in preventing complications of bone marrow transplantation: a meta analysis. Bone Marrow Transplant 1993; 12: 273–282
   Google Scholar
• Messori A, Rampazzo R, Scroccaro G, Martini N. Efficacy of hyperimmune anti-cytomegalovirus immunoglobulins for the prevention of cytomegalovirus infection in recipients of allogeneic bone marrow transplantation: a metaanalysis. Bone Marrow Transplant 1994; 13: 163–167
   PubMed Web of Science ®Google Scholar
• Bowden R A, Fisher L D, Rogers K, et al. Cytomegalovirus (CMV)-specific intravenous immunoglobulin for the prevention of primary CMV infection and disease after marrow transplant. J Infect Dis 1991; 164: 483–487
   PubMed Web of Science ®Google Scholar
• Guglielmo B J, Wong-Beringer A, Linker C A. Immune globulin therapy in allogeneic bone marrow transplant: a critical review. Bone Marrow Transplant 1994; 13: 499–510
   PubMed Web of Science ®Google Scholar
• Sullivan K M, Kopecky K J, Jocum J, et al. Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation. N Eng J Med 1990; 323: 705–712
   PubMed Web of Science ®Google Scholar
• Wolff S N, Fay J W, Herzig R H, et al. High-dose intravenous immunoglobulin to prevent infections in patients undergoing autologous bone marrow transplantation or severe myelosuppressive therapy. Ann Intern Med 1993; 118: 937–942
   PubMed Web of Science ®Google Scholar
• Meyers J D, Reed E C, Shepp D H, et al. Acyclovir for prevention of cytomegalovirus infection and disease after allogeneic marrow transplantation. N Engl J Med 1988; 318: 70–75
   PubMed Web of Science ®Google Scholar
• Prentice H G, Gluckman E, Powles R L, et al. Impact of long-term acyclovir on cytomegalovirus infection and survival after allogeneic bone marrow transplantation. Lancet 1994; 343: 749–753
   PubMed Web of Science ®Google Scholar
• Goodrich J M, Bowden R A, Fisher L, et al. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann Intern Med 1993; 118: 173–178
   PubMed Web of Science ®Google Scholar
• Winston D J, Ho W G, Bartoni K, et al. Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients. Ann Intern Med 1993; 118: 179–184
   PubMed Web of Science ®Google Scholar
• Salzberger B, Bowden R A, Hackman R C, et al. Neutropenia in allogeneic marrow transplant recipients receiving ganciclovir for prevention of cytomegalovirus disease: Risk factors and outcome. Blood 1997; 90: 2502–2508
   PubMed Web of Science ®Google Scholar
• Schmidt G M, Horak D A, Niland J C, et al. A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplant patients. N Engl J Med 1991; 324: 1005–1011
   PubMed Web of Science ®Google Scholar
• Goodrich J M, Mori M, Gleaves C A, et al. Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplant. N Engl J Med 1991; 325: 1601–1607
   PubMed Web of Science ®Google Scholar
• Boeckh M, Gooley T A, Myerson D, et al. Cytomegalovirus pp65 antigenemiaguided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study. Blood 1996; 88: 4063–4071
   PubMed Web of Science ®Google Scholar
• Stocchi R, Szydlo R, Craddock C, et al. A comparison of prophylactic vs preemptive ganciclovir to prevent cytomegalovirus disease after T-depleted volunteer unrelated donor bone marrow transplantation. Bone Marrow Transplant 1999; 23: 705–709
   Google Scholar
• Beockh M, Gooley T A, Bowden R A. Effect of high-dose acyclovir on survival in allogeneic marrow transplant recipients who received ganciclovir at engraftment or for cytomegalovirus pp65 antigenemia. J Infect Dis 1998; 178: 1153–1157
   Google Scholar
• Singhal S, Mehta J, Powles R, et al. Three weeks of ganciclovir for cytomegalovirus after allogeneic bone marrow transplantation. Bone Marrow Transplant 1995; 15: 777–781
   PubMed Web of Science ®Google Scholar
• Verdonck L F, Dekker A W, Rozenberg-Arska M, et al. A risk-adapted approach with a short course of ganciclovir to prevent cytomegalovirus (CMV) pneumonia in CMV-seropositive recipients of allogeneic bone marrow transplants. Clin Infect Dis 1997; 24: 901–907
   Google Scholar
• Zaia J, Gallez-Hawkins G M, Longmate J, et al. Late bacterial and fungal sepsis and mortality after BMT are increased by duration of early ganciclovir preemptive therapy for CMV infection. (Abstract 2128). Blood 1998; 92: 518a
   Google Scholar
• Moretti S, Zikos P, Van Lint M T, et al. Foscarnet vs ganciclovir for cytomegalovirus (CMV) antibenemia after allogeneic hemopoietic stem cell transplantation (HSCT): a ramdomized study. Bone Marrow Transplant 1998; 22: 175–180
   PubMed Web of Science ®Google Scholar
• Gacigalupo A, Bregante S, Tedone E, et al. Combined foscarnet-ganciclovir treatment for cytomegalovirus infections after allogeneic hemopoietic stem cell transplantation. Transplantation 1995; 62: 376–380
   Google Scholar
• Erice A, Borrell N, Li W, et al. Ganciclovir susceptibilities and analysis of UL97 region in cytomegalovirus (CMV) isolates from bone marrow recipients with CMV disease after antiviral prophylaxis. J Infect Dis 1998; 178: 531–534
   Google Scholar
• Slavin M A, Bindra R R, Gleaves C A, et al. Ganciclovir sensitivity of cytomegalovirus at diagnosis and during treatment of cytomegalovirus pneumonia in marrow transplant recipients. Antimicrob Agents Chemother 1993; 37: 1360–1363
   Google Scholar
• Drew W L, Miner R C, Busch D F, et al. Prevalence of resistance in patients receiving ganciclovir for serious cytomegalovirus infection. J Infect Dis 1991; 163: 716–719
   PubMed Web of Science ®Google Scholar
• Chou S. Antiviral drug resistance in human cytomegalovirus. Transplant Infect Dis 1999; 1: 105–114
   PubMedGoogle Scholar
• Chou S, Guentzel S, Michels R, et al. Frequency of UL97 phosphotransferase mutations related to ganciclovir resistance in clinical cytomegalovirus isolates. J Infect Dis 1995; 172: 239–242
   PubMed Web of Science ®Google Scholar
• Smith I L, Cherrington J M, Jiles R E, et al. High-level resistance of cytomegalovirus to ganciclovir is associated with alterations in both the UL97 and DNA polymerase genes. J Infect Dis 1997; 176: 69–77
   PubMed Web of Science ®Google Scholar
• Razis E, Cook P, Mittelman A, et al. Treatment of ganciclovir resistant cytomegalovirus with foscarnet: a report of two cases occurring after bone marrow transplantation. Leuk Lymphom 1994; 12: 477–480
   PubMed Web of Science ®Google Scholar
• Baldanti F, Underwood M R, Stanat S C, et al. Single amino acid changes in the DNA polymerase confer foscarnet resistance and slow-growth phenotype, while mutations in the UL97-encoded phosphotransferase confer ganciclovir resistance in three double-resistant human cytomegalovirus strains recovered from patients with AIDS. J Virology 1996; 70: 1390–1395
   PubMed Web of Science ®Google Scholar
• Quinnan G V, Jr, Kirmani N, Rook A H, et al. Cytotoxic T cells in cytomegalovirus infections. HLA-restricted T-lymphocyte and non-T-lymphocyte cytotoxic responses correlate with recovery from cytomegalovirus infection in bone marrow transplant recipients. N Engl J Med 1982; 307: 7–13
   PubMed Web of Science ®Google Scholar
• Reusser P, Riddel S R, Meyers S D, et al. Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: pattern of recovery and correlation with cytomegalovirus infection and disease. Blood 1991; 78: 1373–1380
   PubMed Web of Science ®Google Scholar
• Quinnan G V, Jr, Burns W H, Kirmani N, et al. HLA-restricted cytotoxic T lymphocytes are an early immune response and important defense mechanism in cytomegalovirus infections. Rev Infect Dis 1984; 6: 156–163
   PubMedGoogle Scholar
• Riddell S R, Walter B A, Gilbert M J, Greenberg P D. Selective reconstitution of CD8 + cytotoxic T lymphocyte responses in immunodeficient bone marrow transplant recipients by the adoptive transfer of T cell clones. Bone Marrow Transplant 1994; 14: S78–S84
   Google Scholar
• Riddell S R, Watanabe K S, Goodrich J M, et al. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T-cell clones. Science 1992; 257: 238–241
   PubMed Web of Science ®Google Scholar
• Riddell S R, Reusser P, Greenberg P D. Cytotoxic T cells for sytomegalovirus: a potential therapy for immunocompromised hosts. Rev Infect 1991; 13: 966–973
   Google Scholar
• Atkinson K, Nivison-Smith I, Dodds A, et al. A comparison of the pattern of interstitial pneumonitis following allogeneic bone marrow transplantation before and after the introduction of prophylactic ganciclovir therapy in 1989. Bone Marrow Transplant 1998; 21: 691–695
   PubMed Web of Science ®Google Scholar
• Li C R, Greenberg P D, Gilbert M J, et al. Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: correlation with CMV disease and effect of ganciclovir prophylaxis. Blood 1994; 83: 1971–1979
   PubMed Web of Science ®Google Scholar
• Appelbaum F R. Choosing the source of stem cells for allogeneic transplantation: no longer a peripheral issue. Blood 1999; 94: 381–383
   PubMed Web of Science ®Google Scholar
• Krause H, Hebart H, Jahn G, et al. Screening for CMV-specific T cell proliferation to identify patients at risk of developing late onset CMV disease. Bone Marrow Transplant 1997; 19: 1111–1116
   PubMed Web of Science ®Google Scholar
• Gor D, Sabin C, Prentice H G, et al. Longitudinal fluctuations in cytomegalovirus load in bone marrow transplant patients: relationship between peak virus load, donor/recipient serostatus, acute GVHD and CMV disease. Bone Marrow Transplant 1998; 21: 597–605
   PubMed Web of Science ®Google Scholar
• Zaia J A, Gallez-Hawkins G M, Teftmeier B R, et al. Late cytomegalovirus disease in marrow transplantation is predicted by virus load in plasma. J Infect Dis 1997; 176: 782–785
   PubMed Web of Science ®Google Scholar
• Ljungman P, Aschan J, Azinge J N, et al. Cytomegalovirus viraemia and specific T-helper cell responses as predictors of disease after allogeneic marrow transplantation. Br J Hematol 1993; 83: 118–124
   PubMed Web of Science ®Google Scholar
• Lazzarotto T, Varani S, Spezzacatena P, et al. Delayed acquisition of high-avidity anti-cytomegalovirus antibody is correlated with prolonged antigenemia in solid organ transplant recipients. J Infect Dis 1998; 178: 1145–1149
   PubMedGoogle Scholar